Literature DB >> 6873146

Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers.

J Godbillon, A Gerardin, V A John, W Theobald.   

Abstract

A potential pharmacokinetic interaction between the beta-blocking drug, metoprolol, and the diuretic, chlorthalidone, has been investigated in three single or multiple dose studies in healthy volunteers. The pharmacokinetic profile of metoprolol 100 mg was not affected by pretreatment with or co-administration of chlorthalidone 25 mg twice daily. Similarly, the pre-dosing steady-state level of chlorthalidone during chronic treatment and its blood level profile after a single 25 mg dose were not affected by metoprolol. The bioavailabilities of the 2 drugs administered in combination were identical to those observed when each drug was administered alone. These studies demonstrate that there is no pharmacokinetic interaction between metoprolol and chlorthalidone when doses of 100 and 25 mg, respectively, are co-administered twice daily.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6873146     DOI: 10.1007/bf00542217

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Dose-dependent acebutolol disposition after oral administration.

Authors:  P J Meffin; R A Winkle; F A Peters; D C Harrison
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

3.  Antihypertensive effect of atenolol alone or combined with chlorthalidone in patients with essential hypertension.

Authors:  M Velasco; J Guevara; J Morillo; A Ramírez; A Urbina-Quintana; O Hernández-Pieretti
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

4.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Antihypertensive activity of a fixed combination of oxprenolol and chlorthalidone in mild to moderate arterial hypertension.

Authors:  M Motolese; E Agabiti-Rosei; A Carotti; P Innocenti; C Montervino; E Solinas; M Toso; G Muiesan
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980

6.  Pharmacokinetic studies with chlorthalidone (Hygroton) in man.

Authors:  W Riess; U C Dubach; D Burckhardt; W Theobald; P Vuillard; M Zimmerli
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

7.  The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.).

Authors:  A A Gulaid; I M James; C M Kaye; O R Lewellen; E Roberts; M Sankey; J Smith; R Templeton; R J Thomas
Journal:  Biopharm Drug Dispos       Date:  1981 Apr-Jun       Impact factor: 1.627

8.  Comparison of the antihypertensive effect of propranolol and practolol combined with chlorthalidone.

Authors:  G G Geyskes; A Stutterheim; P Boer; E J Mees
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

9.  Metoprolol with and without chlorthalidone in hypertension.

Authors:  M Kubik; M Kendall; A Ebbutt; V John
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

10.  Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.

Authors:  H L Fleuren; T A Thien; C P Verwey-van Wissen; J M van Rossum
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

View more
  2 in total

1.  A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.

Authors:  K Sabanathan; C M Castleden; H K Adam; J Ryan; T J Fitzsimons
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.